| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quantitative Trait Loci | 15 | 2022 | 621 | 1.890 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 1713 | 1.700 |
Why?
|
| Lung Neoplasms | 28 | 2014 | 2380 | 1.590 |
Why?
|
| Chromosome Mapping | 9 | 2022 | 1079 | 1.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2014 | 1132 | 1.310 |
Why?
|
| Animals, Outbred Strains | 2 | 2018 | 17 | 1.140 |
Why?
|
| Behavior, Animal | 6 | 2016 | 383 | 1.080 |
Why?
|
| Fear | 7 | 2015 | 80 | 1.000 |
Why?
|
| Alcoholism | 2 | 2022 | 183 | 0.750 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2010 | 2550 | 0.690 |
Why?
|
| Crosses, Genetic | 6 | 2014 | 171 | 0.640 |
Why?
|
| Organ Size | 2 | 2018 | 375 | 0.590 |
Why?
|
| Testis | 1 | 2018 | 152 | 0.570 |
Why?
|
| Genetics, Behavioral | 2 | 2013 | 22 | 0.530 |
Why?
|
| Genetic Markers | 2 | 2016 | 477 | 0.500 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1993 | 0.500 |
Why?
|
| Mice | 19 | 2022 | 11993 | 0.490 |
Why?
|
| Anxiety | 2 | 2014 | 316 | 0.470 |
Why?
|
| Motor Activity | 4 | 2015 | 326 | 0.470 |
Why?
|
| Genotype | 6 | 2018 | 1858 | 0.460 |
Why?
|
| Chromosomes | 1 | 2014 | 99 | 0.460 |
Why?
|
| Phenotype | 9 | 2022 | 2480 | 0.440 |
Why?
|
| Precision Medicine | 3 | 2014 | 421 | 0.430 |
Why?
|
| Carcinoma, Small Cell | 4 | 2014 | 133 | 0.410 |
Why?
|
| Animals | 25 | 2022 | 27783 | 0.410 |
Why?
|
| Alleles | 2 | 2017 | 1138 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2022 | 2440 | 0.400 |
Why?
|
| Models, Animal | 1 | 2013 | 278 | 0.390 |
Why?
|
| Methamphetamine | 2 | 2015 | 89 | 0.380 |
Why?
|
| Conditioning, Classical | 5 | 2015 | 37 | 0.380 |
Why?
|
| Body Weight | 2 | 2019 | 456 | 0.380 |
Why?
|
| Male | 38 | 2022 | 43249 | 0.350 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 538 | 0.350 |
Why?
|
| Neoplasm Staging | 13 | 2011 | 2022 | 0.350 |
Why?
|
| Carboplatin | 7 | 2010 | 325 | 0.350 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 2347 | 0.310 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 424 | 0.310 |
Why?
|
| Early Detection of Cancer | 3 | 2013 | 427 | 0.310 |
Why?
|
| Mice, Inbred DBA | 6 | 2014 | 150 | 0.290 |
Why?
|
| Quality of Life | 8 | 2008 | 1699 | 0.290 |
Why?
|
| Mice, Inbred Strains | 5 | 2014 | 309 | 0.270 |
Why?
|
| Health Status | 3 | 2008 | 370 | 0.270 |
Why?
|
| Computational Biology | 3 | 2018 | 556 | 0.270 |
Why?
|
| Deoxycytidine | 3 | 2007 | 212 | 0.250 |
Why?
|
| Female | 32 | 2019 | 47186 | 0.240 |
Why?
|
| Basolateral Nuclear Complex | 2 | 2015 | 3 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 9 | 2015 | 3303 | 0.230 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 473 | 0.220 |
Why?
|
| Humans | 44 | 2019 | 91074 | 0.220 |
Why?
|
| Databases, Genetic | 2 | 2017 | 270 | 0.210 |
Why?
|
| Survival Analysis | 9 | 2010 | 1500 | 0.210 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 181 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2014 | 113 | 0.200 |
Why?
|
| Pedigree | 2 | 2014 | 970 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 282 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 1183 | 0.190 |
Why?
|
| Central Nervous System Stimulants | 3 | 2015 | 221 | 0.180 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.180 |
Why?
|
| Neoplasms | 5 | 2014 | 3053 | 0.180 |
Why?
|
| Quinazolines | 2 | 2006 | 214 | 0.180 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 66 | 0.180 |
Why?
|
| Treatment Outcome | 14 | 2011 | 8436 | 0.170 |
Why?
|
| Nanotechnology | 1 | 2011 | 69 | 0.170 |
Why?
|
| Aged | 17 | 2019 | 19574 | 0.170 |
Why?
|
| Thinness | 1 | 2019 | 46 | 0.170 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2015 | 669 | 0.170 |
Why?
|
| Muscle Development | 1 | 2019 | 42 | 0.160 |
Why?
|
| Ethanol | 1 | 2022 | 258 | 0.160 |
Why?
|
| Body Composition | 1 | 2019 | 71 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 121 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1404 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2011 | 882 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 183 | 0.160 |
Why?
|
| Middle Aged | 19 | 2019 | 26555 | 0.160 |
Why?
|
| ErbB Receptors | 3 | 2011 | 499 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2019 | 236 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2010 | 6847 | 0.150 |
Why?
|
| Inbreeding | 3 | 2013 | 45 | 0.150 |
Why?
|
| Health Status Indicators | 1 | 2007 | 103 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2011 | 390 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2011 | 613 | 0.140 |
Why?
|
| Genetic Linkage | 1 | 2018 | 624 | 0.130 |
Why?
|
| Sulindac | 1 | 2006 | 8 | 0.130 |
Why?
|
| Electroshock | 2 | 2015 | 17 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 94 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 265 | 0.130 |
Why?
|
| Dendritic Spines | 1 | 2015 | 15 | 0.130 |
Why?
|
| Adult | 16 | 2019 | 27147 | 0.130 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2015 | 20 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 866 | 0.130 |
Why?
|
| Dopaminergic Neurons | 1 | 2015 | 26 | 0.130 |
Why?
|
| Camptothecin | 2 | 2007 | 198 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2007 | 1144 | 0.130 |
Why?
|
| Disease Progression | 5 | 2008 | 1493 | 0.120 |
Why?
|
| Spectrum Analysis | 2 | 2011 | 118 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1559 | 0.120 |
Why?
|
| Genetics, Population | 1 | 2018 | 413 | 0.120 |
Why?
|
| Models, Genetic | 2 | 2013 | 962 | 0.120 |
Why?
|
| Face | 1 | 2015 | 118 | 0.120 |
Why?
|
| Paclitaxel | 6 | 2007 | 499 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3716 | 0.120 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 45 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 80 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 82 | 0.110 |
Why?
|
| Skull | 1 | 2015 | 259 | 0.110 |
Why?
|
| Hybridization, Genetic | 1 | 2014 | 107 | 0.110 |
Why?
|
| Breeding | 1 | 2013 | 41 | 0.110 |
Why?
|
| Zinc Fingers | 1 | 2013 | 58 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 70 | 0.110 |
Why?
|
| Neutropenia | 2 | 2009 | 216 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2014 | 3442 | 0.100 |
Why?
|
| Goals | 1 | 2013 | 67 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 222 | 0.100 |
Why?
|
| Melanoma | 2 | 2004 | 475 | 0.100 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 183 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2014 | 285 | 0.100 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 124 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 500 | 0.100 |
Why?
|
| Receptors, Cannabinoid | 1 | 2012 | 5 | 0.100 |
Why?
|
| Prognosis | 7 | 2011 | 3825 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2012 | 81 | 0.100 |
Why?
|
| Protons | 1 | 2002 | 101 | 0.090 |
Why?
|
| Survival Rate | 6 | 2011 | 1898 | 0.090 |
Why?
|
| Acoustic Stimulation | 1 | 2012 | 127 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2012 | 132 | 0.090 |
Why?
|
| Indazoles | 1 | 2011 | 60 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2018 | 1384 | 0.090 |
Why?
|
| Adiposity | 1 | 2011 | 76 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2011 | 234 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 95 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2012 | 255 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 315 | 0.090 |
Why?
|
| Cues | 1 | 2012 | 176 | 0.090 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 68 | 0.090 |
Why?
|
| Rats | 2 | 2013 | 4043 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 304 | 0.090 |
Why?
|
| Skin Diseases, Infectious | 1 | 2009 | 12 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 1374 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2004 | 1713 | 0.080 |
Why?
|
| Carcinogenicity Tests | 1 | 2009 | 5 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 925 | 0.080 |
Why?
|
| Sigmoidoscopy | 1 | 2009 | 36 | 0.080 |
Why?
|
| Reward | 1 | 2011 | 198 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2010 | 968 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 603 | 0.080 |
Why?
|
| Pemetrexed | 1 | 2009 | 76 | 0.080 |
Why?
|
| Glutamates | 1 | 2009 | 88 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2002 | 784 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 1169 | 0.080 |
Why?
|
| Salvage Therapy | 3 | 2011 | 233 | 0.080 |
Why?
|
| Carcinoma | 1 | 2001 | 438 | 0.080 |
Why?
|
| Guanine | 1 | 2009 | 207 | 0.080 |
Why?
|
| Fatigue | 1 | 2009 | 175 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 186 | 0.070 |
Why?
|
| Anemia | 1 | 2009 | 133 | 0.070 |
Why?
|
| Bevacizumab | 1 | 2009 | 269 | 0.070 |
Why?
|
| Palliative Care | 1 | 1999 | 264 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1248 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2011 | 454 | 0.070 |
Why?
|
| Adenoma | 1 | 2009 | 251 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 854 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 455 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2008 | 478 | 0.070 |
Why?
|
| Proteins | 1 | 2012 | 800 | 0.070 |
Why?
|
| Skin | 1 | 2009 | 586 | 0.070 |
Why?
|
| Brain | 1 | 2016 | 2327 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2008 | 791 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 266 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 572 | 0.060 |
Why?
|
| Neurons | 1 | 2013 | 1597 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 1095 | 0.060 |
Why?
|
| Mutation | 3 | 2011 | 4203 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 143 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2015 | 2033 | 0.050 |
Why?
|
| Breath Tests | 1 | 2013 | 58 | 0.050 |
Why?
|
| Taxoids | 2 | 2008 | 125 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 341 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2011 | 2345 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2007 | 863 | 0.050 |
Why?
|
| Peptide Synthases | 1 | 2022 | 12 | 0.050 |
Why?
|
| Age Factors | 3 | 2012 | 1876 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 591 | 0.050 |
Why?
|
| Sex Factors | 2 | 2014 | 1082 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.050 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2785 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2008 | 4367 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.040 |
Why?
|
| Remission Induction | 2 | 2004 | 756 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 134 | 0.040 |
Why?
|
| Prevalence | 2 | 2009 | 1265 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 180 | 0.040 |
Why?
|
| Cetuximab | 1 | 2010 | 116 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 200 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2005 | 681 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2008 | 34 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2004 | 291 | 0.040 |
Why?
|
| Psychological Tests | 1 | 2007 | 91 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2008 | 231 | 0.030 |
Why?
|
| Risk | 1 | 2008 | 657 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2015 | 17 | 0.030 |
Why?
|
| Time Factors | 2 | 2006 | 5378 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 204 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2006 | 265 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2009 | 9400 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 231 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1877 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 732 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2007 | 887 | 0.030 |
Why?
|
| Lod Score | 1 | 2014 | 152 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 228 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2014 | 36 | 0.030 |
Why?
|
| Vomiting | 1 | 2006 | 198 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 419 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2004 | 338 | 0.030 |
Why?
|
| Hindlimb | 1 | 2014 | 96 | 0.030 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2013 | 5 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 316 | 0.030 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2013 | 10 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2013 | 44 | 0.030 |
Why?
|
| Corticosterone | 1 | 2013 | 35 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1806 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 1 | 2013 | 64 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 81 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2711 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 326 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 2375 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 11 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 439 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 982 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2416 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1935 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 694 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2012 | 48 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1892 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2001 | 40 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2001 | 60 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 690 | 0.020 |
Why?
|
| International Agencies | 1 | 2011 | 34 | 0.020 |
Why?
|
| Craniotomy | 1 | 2001 | 89 | 0.020 |
Why?
|
| Genome | 1 | 2014 | 395 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 356 | 0.020 |
Why?
|
| Locomotion | 1 | 2012 | 140 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1226 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 159 | 0.020 |
Why?
|
| Skin Diseases, Viral | 1 | 2009 | 3 | 0.020 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2009 | 8 | 0.020 |
Why?
|
| Dermatomycoses | 1 | 2009 | 9 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 673 | 0.020 |
Why?
|
| Leukopenia | 1 | 2009 | 67 | 0.020 |
Why?
|
| Duodenal Neoplasms | 1 | 2009 | 19 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 95 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2682 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 120 | 0.020 |
Why?
|
| Duodenum | 1 | 2009 | 105 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2009 | 178 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 6502 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 1066 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2001 | 286 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 2077 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 9411 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 201 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2001 | 475 | 0.020 |
Why?
|
| Vinblastine | 1 | 2007 | 99 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1999 | 321 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3031 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 268 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 97 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 2053 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 630 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1609 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2020 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 2510 | 0.020 |
Why?
|
| Colon | 1 | 2009 | 522 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1196 | 0.020 |
Why?
|
| Mass Screening | 1 | 2010 | 646 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 3204 | 0.020 |
Why?
|
| United States | 1 | 2008 | 7188 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 355 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 3790 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 187 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 219 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 809 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 568 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 453 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 888 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 468 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 214 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 988 | 0.010 |
Why?
|
| Child | 1 | 2012 | 7273 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 3029 | 0.010 |
Why?
|